Ir para o conteúdo
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Avançada
  • The Prolyl Hydroxylase Inhibit...
  • Citar
  • Enviar por SMS
  • Enviar por email
  • Imprimir
  • Exportar registo
    • Exportar para RefWorks
    • Exportar para EndNoteWeb
    • Exportar para EndNote
  • Permanent link
The Prolyl Hydroxylase Inhibitor BIQ/FG-2216 Stabilises HIF-1 alpha and Upregulates VEGF in vitro: A Potential Strategy For Difficult CTO Lesions in Patients.

The Prolyl Hydroxylase Inhibitor BIQ/FG-2216 Stabilises HIF-1 alpha and Upregulates VEGF in vitro: A Potential Strategy For Difficult CTO Lesions in Patients.

Detalhes bibliográficos
Main Authors: Barnett, G, Flashman, E, Kelly, D, Schofield, C, Gershlick, A
Formato: Conference item
Publicado em: 2013
  • Exemplares
  • Descrição
  • Registos relacionados
  • Registo fonte
Descrição
Resumo:

Registos relacionados

  • 74 Pro-Angiogenic Effects of the Prolyl-hydroxylase Inhibitor FG-2216/BIQ: Therapeutic Angiogenesis for the Treatment of Chronic Total Occlusions.
    Por: Barnett, G, et al.
    Publicado em: (2014)
  • Pro-angiogenic effects of proly-hydroxylase inhibitor FG-2216 and potential for use in a novel strategy of therapeutic angiogenesis for difficult cases of coronary total occlusion
    Por: Barnett, G, et al.
    Publicado em: (2014)
  • Enhanced Endothelial Tubule Formation in Response to Proly-Hydroxylase Inhibitor FG-2216: A Step Towards Therapeutic Angiogenesis in Chronic Total Occlusions
    Por: Barnett, G, et al.
    Publicado em: (2012)
  • Investigating the dependence of the hypoxia-inducible factor hydroxylases (factor inhibiting HIF and prolyl hydroxylase domain 2) on ascorbate and other reducing agents.
    Por: Flashman, E, et al.
    Publicado em: (2010)
  • Regulation of HIF: prolyl hydroxylases.
    Por: Stolze, I, et al.
    Publicado em: (2006)

Opções de Pesquisa

  • Histórico de Pesquisas
  • Pesquisa Avançada

Encontrar Mais

  • Percorrer o Catálogo
  • Percorrer por ordem alfabética
  • Explore Channels
  • Bibliografia Recomendada
  • Novos exemplares

Precisa de ajuda?

  • Dicas de Pesquisa
  • Serviço de Referência
  • FAQs